Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
92.06
Dollar change
+2.57
Percentage change
2.87
%
Index- P/E105.67 EPS (ttm)0.87 Insider Own2.03% Shs Outstand188.60M Perf Week1.31%
Market Cap17.47B Forward P/E35.21 EPS next Y2.61 Insider Trans-4.53% Shs Float185.93M Perf Month8.14%
Income167.65M PEG2.46 EPS next Q0.32 Inst Own98.75% Short Float1.65% Perf Quarter-1.05%
Sales2.42B P/S7.22 EPS this Y76.86% Inst Trans2.04% Short Ratio2.18 Perf Half Y12.12%
Book/sh26.25 P/B3.51 EPS next Y69.94% ROA2.54% Short Interest3.06M Perf Year-5.59%
Cash/sh5.66 P/C16.27 EPS next 5Y43.00% ROE3.51% 52W Range76.02 - 99.56 Perf YTD-4.52%
Dividend Est.- P/FCF279.23 EPS past 5Y- ROI3.00% 52W High-7.53% Beta0.31
Dividend TTM- Quick Ratio1.57 Sales past 5Y10.23% Gross Margin76.15% 52W Low21.10% ATR (14)1.78
Dividend Ex-Date- Current Ratio2.51 EPS Y/Y TTM16.20% Oper. Margin8.01% RSI (14)63.40 Volatility1.80% 1.90%
Employees3401 Debt/Eq0.23 Sales Y/Y TTM18.16% Profit Margin6.93% Recom1.73 Target Price110.19
Option/ShortYes / Yes LT Debt/Eq0.13 EPS Q/Q8269.23% Payout0.00% Rel Volume0.92 Prev Close89.49
Sales Surprise1.16% EPS Surprise-43.73% Sales Q/Q25.23% EarningsApr 24 AMC Avg Volume1.41M Price92.06
SMA203.68% SMA505.03% SMA2003.40% Trades Volume1,298,900 Change2.87%
Date Action Analyst Rating Change Price Target Change
Nov-15-23Initiated Wells Fargo Overweight $100
Oct-23-23Upgrade Bernstein Underperform → Mkt Perform $82
Sep-28-23Initiated Raymond James Mkt Perform
Sep-18-23Initiated UBS Buy $120
Jul-27-23Initiated Scotiabank Sector Perform $95
Jul-05-23Upgrade BMO Capital Markets Market Perform → Outperform $102
Jun-14-23Resumed Credit Suisse Outperform $120
Mar-21-23Initiated Bernstein Underperform $81
Feb-22-23Downgrade Oppenheimer Outperform → Perform
Feb-21-23Initiated Citigroup Neutral $116
Apr-23-24 11:36AM
Apr-22-24 04:26PM
09:16AM
Apr-17-24 10:01AM
Apr-12-24 07:00PM
08:00AM Loading…
Apr-10-24 08:00AM
Apr-01-24 07:01PM
Mar-17-24 08:50AM
Mar-16-24 05:06AM
Mar-12-24 08:30AM
Mar-11-24 10:00AM
Mar-08-24 01:31AM
Mar-07-24 08:30AM
Mar-01-24 09:00AM
Feb-27-24 12:03AM
02:36PM Loading…
Feb-26-24 02:36PM
02:12PM
Feb-23-24 04:29PM
12:33PM
11:34AM
07:21AM
05:43AM
04:25AM
Feb-22-24 06:00PM
05:15PM
04:42PM
04:23PM
04:03PM
Feb-19-24 09:15AM
Feb-15-24 10:00AM
01:10PM Loading…
Feb-13-24 01:10PM
Feb-08-24 04:10PM
08:00AM
Feb-07-24 05:21AM
Feb-06-24 08:30AM
Jan-24-24 11:21AM
Jan-23-24 08:00AM
Jan-20-24 05:06AM
Jan-15-24 09:45AM
Jan-10-24 06:16PM
Jan-03-24 08:00AM
Dec-21-23 06:14AM
Dec-20-23 05:08PM
04:05PM
Dec-14-23 07:05PM
Dec-05-23 11:01AM
Dec-02-23 05:06AM
Dec-01-23 11:31AM
Nov-29-23 09:13PM
06:30AM
Nov-28-23 11:09AM
08:30AM
Nov-16-23 08:47AM
Nov-10-23 12:58AM
Nov-09-23 04:43PM
03:49AM
Nov-08-23 05:19AM
Nov-07-23 07:09PM
05:07PM
02:24PM
Nov-06-23 07:20PM
Nov-04-23 05:06AM
Nov-03-23 01:23AM
Nov-02-23 05:02PM
12:17PM
08:44AM
07:15AM
Nov-01-23 06:30PM
05:55PM
05:02PM
04:05PM
04:02PM
Oct-27-23 07:15AM
Oct-26-23 11:28AM
10:02AM
Oct-25-23 10:02AM
Oct-23-23 09:50AM
Oct-20-23 04:20PM
04:11PM
04:05PM
Oct-19-23 12:17PM
08:15AM
Oct-18-23 12:10PM
Oct-17-23 08:30AM
Sep-23-23 05:06AM
Sep-21-23 10:00AM
Sep-18-23 10:52AM
09:55AM
Sep-15-23 12:50PM
09:29AM
08:37AM
Sep-11-23 08:30AM
Sep-06-23 08:30AM
Sep-05-23 08:30AM
Sep-02-23 05:06AM
Sep-01-23 11:31AM
Aug-31-23 11:31AM
Aug-30-23 04:05PM
Aug-12-23 05:06AM
Aug-01-23 01:37PM
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESDirectorApr 12 '24Option Exercise63.1020,0001,262,000494,994Apr 15 04:21 PM
BIENAIME JEAN JACQUESDirectorApr 12 '24Sale91.2620,0001,825,200474,994Apr 15 04:21 PM
BIENAIME JEAN JACQUESDirectorApr 11 '24Option Exercise63.1020,0001,262,000494,994Apr 15 04:21 PM
BIENAIME JEAN JACQUESDirectorApr 11 '24Sale90.9920,0001,819,800474,994Apr 15 04:21 PM
Burkhart ErinGVP, Chief Accounting OfficerApr 10 '24Sale90.002,286205,74016,156Apr 12 03:07 PM
Davis George EricEVP, Chief Legal OfficerMar 28 '24Sale88.3424,6022,173,34155,856Apr 01 04:54 PM
Slamon DennisDirectorMar 18 '24Option Exercise79.7010,000797,00040,809Mar 20 05:13 PM
BIENAIME JEAN JACQUESDirectorMar 06 '24Sale86.711,00086,713560,203Mar 07 05:35 PM
FUCHS HENRY JPresident, Worldwide R&DMar 05 '24Sale85.1835,3413,010,396212,117Mar 07 06:54 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 05 '24Sale87.074,000348,28094,047Mar 07 05:32 PM
BIENAIME JEAN JACQUESDirectorMar 05 '24Sale85.511,00085,510561,203Mar 07 05:35 PM
BIENAIME JEAN JACQUESDirectorFeb 27 '24Sale90.351,00090,350562,203Feb 29 05:05 PM
BIENAIME JEAN JACQUESDirectorFeb 09 '24Option Exercise63.1015,000946,500434,602Feb 12 05:20 PM
BIENAIME JEAN JACQUESDirectorFeb 09 '24Sale88.2815,0001,324,200419,602Feb 12 05:20 PM
BIENAIME JEAN JACQUESDirectorFeb 08 '24Option Exercise63.1015,000946,500434,602Feb 12 05:20 PM
BIENAIME JEAN JACQUESDirectorFeb 08 '24Sale89.7715,0001,346,550419,602Feb 12 05:20 PM
BIENAIME JEAN JACQUESDirectorJan 10 '24Option Exercise63.1010,000631,000435,162Jan 11 02:40 PM
BIENAIME JEAN JACQUESDirectorJan 10 '24Sale96.3810,000963,800425,162Jan 11 02:40 PM
BIENAIME JEAN JACQUESDirectorJan 09 '24Option Exercise63.1010,000631,000435,162Jan 11 02:40 PM
BIENAIME JEAN JACQUESDirectorJan 09 '24Sale98.1910,000981,900425,162Jan 11 02:40 PM
BIENAIME JEAN JACQUESDirectorDec 21 '23Option Exercise63.1010,000631,000435,112Dec 22 05:14 PM
BIENAIME JEAN JACQUESDirectorDec 21 '23Sale93.9910,000939,900425,112Dec 22 05:14 PM
Davis George EricEVP, Chief Legal OfficerDec 13 '23Sale95.3013,7641,311,70955,710Dec 14 06:18 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerAug 16 '23Sale90.005,000450,00060,804Aug 17 03:57 PM
FUCHS HENRY JPresident, Worldwide R&DAug 10 '23Sale90.4312,0001,085,111176,187Aug 11 01:59 PM
Guyer Charles GregEVP, Chief Technical OfficerAug 09 '23Sale93.305,360500,10940,041Aug 10 04:47 PM
Davis George EricEVP, Chief Legal OfficerAug 08 '23Sale89.4211,000983,66269,474Aug 09 07:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 08 '23Sale88.296,000529,740422,732Aug 09 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 07 '23Sale88.104,000352,400428,732Aug 09 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 12 '23Option Exercise67.8146,5003,153,165472,713May 16 05:22 PM
MEIER RICHARD ADirectorMay 12 '23Option Exercise67.818,500576,385117,494May 17 06:14 PM
HERON ELAINE JDirectorMay 12 '23Option Exercise67.818,500576,38594,068May 17 06:14 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 11 '23Option Exercise67.8130,0002,034,300456,213May 15 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 11 '23Sale94.6730,0002,840,226426,213May 15 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10 '23Option Exercise67.8130,0002,034,300456,213May 11 05:04 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10 '23Sale94.8530,0002,845,397426,213May 11 05:04 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 09 '23Option Exercise67.8130,0002,034,300456,213May 11 05:04 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 09 '23Sale94.9330,0002,847,973426,213May 11 05:04 PM